Sequana Medical NV
XBRU:SEQUA

Watchlist Manager
Sequana Medical NV Logo
Sequana Medical NV
XBRU:SEQUA
Watchlist
Price: 0.4965 EUR 0.1% Market Closed
Market Cap: €38.1m

P/B

-0.9
Current
82%
Cheaper
vs 3-y average of -5.1

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
-0.9
=
Market Cap
€42.4m
/
Total Equity
€-39.2m

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
-0.9
=
Market Cap
€42.4m
/
Total Equity
€-39.2m

Valuation Scenarios

Sequana Medical NV is trading above its industry average

If P/B returns to its Industry Average (3.5), the stock would be worth €-1.82 (466% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-466%
Maximum Upside
No Upside Scenarios
Average Downside
343%
Scenario P/B Value Implied Price Upside/Downside
Current Multiple -0.9 €0.5
0%
Industry Average 3.5 €-1.82
-466%
Country Average 1.1 €-0.6
-221%

Forward P/B
Today’s price vs future total equity

Not enough data available to calculate forward P/B

Peer Comparison

All Multiples
P/B
P/E
All Countries
Close

Market Distribution

Lower than 100% of companies in Belgium
Percentile
0th
Based on 391 companies
0th percentile
-0.9
Low
0.3 — 0.9
Typical Range
0.9 — 1.7
High
1.7 —
Distribution Statistics
Belgium
Min 0.3
30th Percentile 0.9
Median 1.1
70th Percentile 1.7
Max 292.9

Sequana Medical NV
Glance View

Market Cap
38.1m EUR
Industry
Health Care

Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 60 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.

SEQUA Intrinsic Value
1.0748 EUR
Undervaluation 54%
Intrinsic Value
Price €0.4965
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett